| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Methylnicotinamide is an endogenous metabolite that does not have a well-defined specific therapeutic target. As a derivative of nicotinamide, it may be involved in NAD+ metabolism and cellular energy pathways. Nicotinamide derivatives are known to interact with various enzymes involved in NAD+ biosynthesis and metabolism. The compound's methyl group at the 6-position of the pyridine ring may influence its interactions with biological targets.
|
|---|---|
| ln Vitro |
6-Methylnicotinamide is an endogenous metabolite. As a derivative of nicotinamide, it may be involved in NAD+ metabolism and cellular energy pathways. The compound has been studied for its effects on perovskite solar cells, where it enhances efficiency to 24.33% with excellent environmental stability. Its sudden increase in the acute stages of intracerebral hemorrhage (ICH) exacerbates the condition, suggesting a role in disease pathology.
|
| ln Vivo |
In vivo, 6-methylnicotinamide is an endogenous metabolite whose sudden increase in the acute stages of intracerebral hemorrhage (ICH) exacerbates the condition. This suggests that the compound may play a role in the pathophysiology of ICH. The compound is not used as a therapeutic agent but is studied for its role in metabolism and disease. Specific in vivo efficacy studies for therapeutic applications are not applicable.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 6-methylnicotinamide are not extensively documented. As a nicotinamide derivative, the compound may be studied for its interactions with enzymes involved in NAD+ metabolism, such as nicotinamide phosphoribosyltransferase (NAMPT) or nicotinamide N-methyltransferase (NNMT). Standard assays involve incubating the compound with recombinant enzymes and measuring activity using spectrophotometric or fluorometric methods. The compound is dissolved in DMSO or water and diluted in assay buffer.
|
| Cell Assay |
In vitro cellular assays for 6-methylnicotinamide typically involve treating cells with the compound at concentrations ranging from 1 to 100 μM for 24-72 hours. Cellular NAD+ levels are measured using enzymatic cycling assays or LC-MS. Cell viability is assessed using MTT or other standard assays. The compound is dissolved in DMSO or water as a stock solution and diluted in cell culture medium. The compound's effects on cellular metabolism and energy pathways are assessed.
|
| Animal Protocol |
In vivo animal studies for 6-methylnicotinamide are not typically performed for therapeutic purposes, as the compound is an endogenous metabolite rather than a therapeutic agent. The compound may be studied in animal models of intracerebral hemorrhage to understand its role in disease pathology. Blood and tissue samples are collected for metabolic analysis. The compound is not intended for human therapeutic use.
|
| ADME/Pharmacokinetics |
6-Methylnicotinamide has a molecular weight of 136.15 g/mol and formula C7H8N2O. It is a white solid. The compound is soluble in water and organic solvents. It is an endogenous metabolite. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
6-Methylnicotinamide is intended for research use only and is not approved for human therapeutic applications. As an endogenous metabolite, it is generally considered to have low toxicity. Appropriate safety precautions should be taken when handling, including wearing gloves and protective eyewear. Standard toxicity assessments would include acute toxicity and repeated-dose toxicity studies if required for specific applications. The compound is not intended for human consumption.
|
| References | |
| Additional Infomation |
6-Methylnicotinamide (CAS 6960-22-1) is a pyridinecarboxamide derivative of nicotinamide with a molecular weight of 136.15 g/mol and formula C7H8N2O. It is an endogenous metabolite. The compound has been studied for its effects on perovskite solar cells, enhancing efficiency to 24.33%. Its sudden increase in the acute stages of intracerebral hemorrhage exacerbates the condition. The compound is also known as 6-甲基烟酰胺. It is not approved for clinical use.
|
| Molecular Formula |
C7H8N2O
|
|---|---|
| Molecular Weight |
136.1512
|
| Exact Mass |
136.063
|
| CAS # |
6960-22-1
|
| PubChem CID |
96351
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
289.4±28.0 °C at 760 mmHg
|
| Melting Point |
197-199 °C(lit.)
|
| Flash Point |
128.8±24.0 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
0.35
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IJXDURUAYOKSIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8N2O/c1-5-2-3-6(4-9-5)7(8)10/h2-4H,1H3,(H2,8,10)
|
| Chemical Name |
6-methylpyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~367.24 mM)
H2O : ~3.33 mg/mL (~24.46 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3448 mL | 36.7242 mL | 73.4484 mL | |
| 5 mM | 1.4690 mL | 7.3448 mL | 14.6897 mL | |
| 10 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
